Dr. Sangro on Updated Findings From the CheckMate-459 Trial in Advanced HCC
July 1st 2020Bruno Sangro, MD, PhD, discusses the updated findings from the phase 3 CheckMate-459 trial, which evaluated the use of nivolumab and sorafenib in the treatment of patients with advanced hepatocellular carcinoma.
Read More